Table 23:
Prostate Cancer Stage and Grade Detection in the ERSPC Trial
| Screen Group | Control Group | |||
|---|---|---|---|---|
| n (metastatic) | % | n (metastatic) | % | |
| Total PCs detected | 6,963 | 5,396 | ||
| Tumour (T) stage (metastatic) | ||||
| T1 (M1 or PSA > 100) | 4,136 (32) | 59.4 | 2,613 (45) | 48.4 |
| T2 (M1 or PSA >100) | 1,848 (40) | 26.5 | 1,379 (83) | 25.6 |
| T3 (M1 or PSA >100) | 589 (95) | 8.5 | 865 (226) | 16.0 |
| T4 (M1 or PSA >100) | 88 (54) | 1.3 | 206 (152) | 3.8 |
| Missing | 302 | 4.3 | 333 | 6.2 |
| Tumour grade (metastatic) | ||||
| GS ≤ 6 (M1 or PSA >100) | 4,528 (58) | 65.0 | 2,564 (57) | 47.5 |
| GS = 7 (M1 or PSA >100) | 1,433 (104) | 20.6 | 1,488 (146) | 27.6 |
| GS = 8–10 (M1 or PSA >100) | 574 (29) | 8.2 | 857 (270) | 15.9 |
| Missing | 428 | 6.1 | 487 | 9.0 |
| Risk group (stage, grade, and PSA level) | ||||
| Low (T1 or T2 and GS ≤ 6) | 4,198 (58) | 60.3 | 2,249 | 42.4 |
| Intermediate (T1, T2 and GS = 7) or (T3 and GS ≤ 7) | 1,495 | 21.5 | 1,442 | 26.7 |
| High (T1, T2, or T3 and GS = 8–10; or T4 and any GS, M1, or PSA > 100; or any stage and M1 or PSA > 100) | 515 | 7.4 | 673 | 12.5 |
| M1 or PSA > 100 | 180 | 2.6 | 424 | 7.9 |
| Missing | 575 | 8.3 | 608 | 11.3 |
Abbreviations: ERSPC, European Randomized Study of Screening for Prostate Cancer. GS, Gleason score; M1, distant metastasis present; n, number; PC, prostate caner; PSA, prostate-specific antigen.
Source: Haines et al, 2013. (79)